  | Honvo, G., Reginster, J.-Y., Rannou, F., Rygaert, X., Geerinck, A., Rabenda, V., McAlindon, T., Charles, A., Fuggle, N., Cooper, C., Curtis, E., Arden, N., Avouac, B., & Bruyère, O. (2019). Safety of intra-articular hyaluronic acid injections in osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs and Aging, 36 (suppl 1), 101-127. doi:10.1007/s40266-019-00657-w  Peer Reviewed verified by ORBi |
 | Honvo, G., Leclercq, V., Geerinck, A., Thomas, T., Veronese, N., Charles, A., Rabenda, V., Beaudart, C., Cooper, C., Reginster, J.-Y., & Bruyère, O. (2019). Safety of topical non-steroidal anti-inflammatory drugs in osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs and Aging, 36 (suppl 1), 45-64. doi:10.1007/s40266-019-00661-0 Peer Reviewed verified by ORBi |
 | Honvo, G., Reginster, J.-Y., Rabenda, V., Geerinck, A., Mkinsi, O., Charles, A., Rizzoli, R., Cooper, C., Avouac, B., & Bruyère, O. (2019). Safety of symptomatic slow-acting drugs for osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs and Aging, 36 (suppl 1), 65-99. doi:10.1007/s40266-019-00662-z Peer Reviewed verified by ORBi |
 | Leclercq, V., Beaudart, C., Ajamieh, S., Rabenda, V., Tirelli, E., & Bruyère, O. (November 2018). Poor quality reporting of the meta-analyses in psychology as assessed using the PRISMA Statement. European Journal of Public Health, 28 (4), 509. doi:10.1093/eurpub/cky218.292 Peer Reviewed verified by ORBi |
 | Leclercq, V., Beaudart, C., Ajamieh, S., Rabenda, V., Tirelli, E., & Bruyère, O. (October 2018). The use of PRISMA statement improves the reporting quality of meta-analyses published in the field of psychology. Value in Health Regional Issues, 21, 401. doi:10.1016/j.jval.2018.09.2380 Peer Reviewed verified by ORBi |
 | Rabenda, V., Leclercq, V., Reginster, J.-Y., & Bruyère, O. (April 2018). Critical appraisal of psychometric methods used in validation of patient-reported outcomes measures. Osteoporosis International, 29 S1, 480-481. Peer Reviewed verified by ORBi |
 | Honvo, G., Leclercq, V., GEERINCK, A., Rabenda, V., Beaudart, C., Cooper, C., Reginster, J.-Y., & Bruyère, O. (April 2018). Adverse events associated with topical non-steroidal anti-inflammatory drugs (NSAIDS) in osteoarthritis: a systematic review and meta-analysis of randomized, placebo-controlled trials. Osteoporosis International, 29 S1, 550. Peer Reviewed verified by ORBi |
 | Rabenda, V., Leclercq, V., Reginster, J.-Y., & Bruyère, O. (April 2018). Review of terminology of measurement properties for patient-reported outcomes measures. Osteoporosis International, 29 S1, 482. Peer Reviewed verified by ORBi |
 | Honvo, G., Rabenda, V., GEERINCK, A., Cooper, C., Reginster, J.-Y., & Bruyère, O. (April 2018). Adverse events associated with symptomatic slow-acting drugs in osteoarthritis (SYSADOAS): a systematic review and stratified meta-analysis of randomized, placebo-controlled trials. Osteoporosis International, 29 S1, 549-550. Peer Reviewed verified by ORBi |
 | Beaudart, C., Rabenda, V., Simmons, M., Geerinck, A., Araujo De Carvalho, I., Reginster, J.-Y., Amuthavalli Thiyagarajan, J., & Bruyère, O. (2018). Effects of protein, essential amino acids, B-Hydroxy B-Methylbutyrate, creatine, Dehydroepiandrosterone and fatty acid supplementation on muscle mass, muscle strength and physical performance in older people aged 60 years and over. A systematic review of the litterature. Journal of Nutrition, Health and Aging, 22 (1), 117-130. doi:10.1007/s12603-017-0934-z Peer Reviewed verified by ORBi |
 | Rabenda, V., Beaudart, C., & Bruyère, O. (February 2017). Il n'est jamais trop tard pour apprendre à (bien) lire ... La Méta-Analyse. Ortho-Rhumato, 15 (1), 27-32. |
 | Locquet, M., Honvo, G., Rabenda, V., Van Hees, T., Petermans, J., Reginster, J.-Y., & Bruyère, O. (2017). Adverse Health Events Related to Self-Medication Practices Among Elderly: A Systematic Review. Drugs and Aging, 34 (5), 359-365. doi:10.1007/s40266-017-0445-y Peer Reviewed verified by ORBi |
 | Beaudart, C., Rabenda, V., & Bruyère, O. (September 2016). Il n'est jamais trop tard pour apprendre à (bien) lire ... La revue systématique. Medi-Sphere, 525, 35-38. |
 | Beaudart, C., Rabenda, V., & Bruyère, O. (2016). Il n'est jamais trop tard pour apprendre à (bien) lire ... La revue systématique. Ortho-Rhumato, 14 (6), 37-40. |
 | Beaudart, C., Rabenda, V., & Bruyère, O. (2016). Het is nooit te laat om (goed) te leren lezen ... Systematic review. Gunaïkeia. Société Royale Belge de Gynécologie et d'Obstétrique, 21 (9), 37-40. |
 | Rabenda, V., Bruyère, O., Cooper, C., Rizzoli, R., Buckinx, F., Quabron, A., & Reginster, J.-Y. (2015). Publication outcomes of the abstracts presented at the 2011 European Congress on Osteoporosis, Osteoarthritis and Musculo-Skeletal Diseases (ECCEO-IOF11) : A position paper of the European Society for Clinical and Economical Aspects of Osteoporosis, Osteoarthritis and Musculo-Skeletal Diseases (ESCEO) and the International Osteoporosis and Other Skeletal Diseases Foundation (IOF). Archives of Osteoporosis, 10 (1). doi:10.1007/s11657-015-0216-5 Peer Reviewed verified by ORBi |
 | Rabenda, V., Bruyère, O., Cavalier, E., DEROISY, R., LECART, M.-P., COLLETTE, J., & Reginster, J.-Y. (2015). Serum concentrations of osteoprotegerin (OPG) and dickkope-1 (DKK1) poorly predict bone mineral density changes and fracture incidence in postmenopausal osteoporotic women. Osteoporosis International, 26 (S1), 240. Peer Reviewed verified by ORBi |
 | Rabenda, V., Bruyère, O., Kanis, J., Cooper, C., Rizzoli, R., Buckinx, F., Quabron, A., & Reginster, J.-Y. (2015). Publication outcomes of the abstracts presented at the 2011 European Congress on Osteoporosis, Osteoarthritis and Musculo-skeletal Diseases (ECCEO-IOF11). Osteoporosis International, 26 (S1), 211. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Ben Sedrine, W., Bruyère, O., Evers, S. M., Rabenda, V., & Reginster, J.-Y. (2015). Cost-effectiveness of vitamin D and calcium supplementation in the treatment of elderly women and men with osteoporosis. European Journal of Public Health, 25 (1), 20-25. doi:10.1093/eurpub/cku119 Peer Reviewed verified by ORBi |
 | Beaudart, C., Buckinx, F., Rabenda, V., GILLAIN, S., Cavalier, E., Slomian, J., Petermans, J., Reginster, J.-Y., & Bruyère, O. (2014). The effects of vitamin D on skeletal muscle strength, muscle mass and muscle power: a systematic review and meta-analysis of randomized controlled trials. Journal of Clinical Endocrinology and Metabolism, 99 (11), 4336-4345. doi:10.1210/jc.2014-1742 Peer Reviewed verified by ORBi |
 | Douxfils, J., Buckinx, F., Mullier, F., Minet, V., Rabenda, V., Reginster, J.-Y., Hainaut, P., Bruyère, O., & Dogne, J.-M. (2014). Dabigatran Etexilate and Risk of Myocardial Infarction, Other Cardiovascular Events, Major Bleeding, and All-Cause Mortality: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Journal of the American Heart Association, 3 (3), 000515. doi:10.1161/JAHA.113.000515 Peer Reviewed verified by ORBi |
 | Beaudart, C., Buckinx, F., Rabenda, V., GILLAIN, S., CAVALIER, E., Slomian, J., PETERMANS, J., Reginster, J.-Y., & Bruyère, O. (2014). The effects of vitamin D on skeletal muscle strength, muscle mass and muscle power: a meta-analysis of randomized controlled trials. Osteoporosis International, 25 (2), 46. Peer Reviewed verified by ORBi |
 | Beaudart, C., Buckinx, F., Rabenda, V., CAVALIER, E., Petermans, J., Reginster, J.-Y., & Bruyère, O. (2014). The effects of vitamin D on skeletal muscle strength, muscle mass and muscle power: a meta-analysis of randomized controlled trials. Journal of Frailty and Aging, 3 (1), 27. Peer Reviewed verified by ORBi |
 | Beaudart, C., Buckinx, F., Rabenda, V., GILLAIN, S., CAVALIER, E., Slomian, J., Petermans, J., Reginster, J.-Y., & Bruyère, O. (2014). Les effets d'une supplémentation en vitamine D sur la force, la masse et la puissance musculaire : une méta-analyse d'essais randomisés contrôlés. Gériatrie et Psychologie Neuropsychiatrie du Vieillissement, 12 (1), 73. Peer reviewed |
  | Beaudart, C., Buckinx, F., Rabenda, V., GILLAIN, S., CAVALIER, E., Slomian, J., PETERMANS, J., Reginster, J.-Y., & Bruyère, O. (28 November 2013). Les effets d’une supplémentation en vitamine D sur la force musculaire : une méta-analyse d’essais randomisés contrôlés [Paper presentation]. Journée des Doctorants de l'Ecole Doctorale "SPSS", Bruxelles, Belgium. |
 | Beaudart, C., Buckinx, F., Rabenda, V., GILLAIN, S., CAVALIER, E., Petermans, J., Reginster, J.-Y., & Bruyère, O. (September 2013). Les effets d'une supplémentation en vitamine D sur la force musculaire : une méta-analyse d'essais randomisés contrôlés. Cahiers de l'Année Gérontologique, 5 (1-2), 38. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Ben Sedrine, W., Rabenda, V., Bruyère, O., & Reginster, J.-Y. (April 2013). Cost-effectiveness of vitamin D and calcium supplementation in the treatment of postmenopausal women. Osteoporosis International, 24 (Suppl.1), 198. Peer Reviewed verified by ORBi |
 | Bruyère, O., Nicolet, D., Compère, S., Rabenda, V., Jeholet, P., Zegels, B., Maassen, P., Pire, G., & Reginster, J.-Y. (April 2013). Perception, knowledge, and use by general practitioners of Belgium of a new WHO tool (FRAX ) to assess the 10-year probability of fracture. Rheumatology International, 33 (4), 979-83. doi:10.1007/s00296-012-2461-x Peer Reviewed verified by ORBi |
 | Bruyère, O., Cooper, C., Pavelka, K., Rabenda, V., Buckinx, F., Beaudart, C., & Reginster, J.-Y. (April 2013). Changes in the structure and the symptoms of the osteoarthritis knee and prediction of future knee replacement over an 8-year follow-up period. Osteoporosis International, 24 (Suppl.1), 209. Peer Reviewed verified by ORBi |
 | Rabenda, V., Nicolet, D., Beaudart, C., Bruyère, O., & Reginster, J.-Y. (2013). Relationship between use of antidepressants and risk of fractures: a meta-analysis. Osteoporosis International, 24, 121-137. doi:10.1007/s00198-012-2015-9 Peer Reviewed verified by ORBi |
 | Bruyère, O., Cooper, C., Pavelka, K., Rabenda, V., Buckinx, F., Beaudart, C., & REGINSTER, J.-Y. (2013). Changes in Structure and Symptoms in Knee Osteoarthritis and Prediction of Future Knee Replacement Over 8 Years. Calcified Tissue International, 93, 502-507. doi:10.1007/s00223-013-9781-z Peer Reviewed verified by ORBi |
 | Beaudart, C., Buckinx, F., Rabenda, V., GILLAIN, S., Cavalier, E., Slomian, J., Petermans, J., Reginster, J.-Y., & Bruyère, O. (2013). Les effets d'une supplémentation en vitamine D sur la force, la masse et la puissance musculaire : une méta-analyse d'essais randomisés contrôlés. Revue du Rhumatisme, 80 (S1), 180-A181. Peer Reviewed verified by ORBi |
 | Beaudart, C., Buckinx, F., Rabenda, V., GILLAIN, S., Cavalier, E., Petermans, J., Reginster, J.-Y., & Bruyère, O. (2013). The effects of vitamin D on skeletal muscle strenght : a meta-analysis of randomized controlled trials. European Geriatric Medicine, 4 (S1), 72. Peer reviewed |
 | Bruyère, O., Nicolet, D., Compère, S., Rabenda, V., Jeholet, P., ZEGELS, B., Maassen, P., Pire, G., & Reginster, J.-Y. (June 2012). Perception, knowledge and use by general practitioners of Belgium of the FRAX tool. Annals of the Rheumatic Diseases, 71 (Suppl.3), 716. Peer Reviewed verified by ORBi |
 | Bruyère, O., Zegels, B., LEONORI, L., Rabenda, V., Janssen, A., Bourges, C., & Reginster, J.-Y. (March 2012). Effect of collagen hydrolysate in articular pain: A 6-month randomized, double-blind, placebo controlled study. Osteoporosis International, 23 (Suppl. 2), 362-363. Peer Reviewed verified by ORBi |
 | Bruyère, O., Rabenda, V., & Reginster, J.-Y. (March 2012). Prediction of future knee surgery in patient with osteoarhtritis by the use of a new definition of x-ray progression. Osteoporosis International, 23 (Suppl. 2), 363. Peer Reviewed verified by ORBi |
 | Bruyère, O., Nicolet, D., Compère, S., Rabenda, V., Jeholet, P., Zegels, B., Maassen, P., Pire, G., & Reginster, J.-Y. (March 2012). Perception, knowledge and use by general practitioners of Belgium of the FRAX tool. Osteoporosis International, 23 (Suppl. 2), 363-364. Peer Reviewed verified by ORBi |
 | Rabenda, V., Bruyère, O., & REGINSTER, J.-Y. (2012). Risk of nonvertebral fractures among elderly postmenopausal women using antidepressants. BONE, 51 (4), 674-679. doi:10.1016/j.bone.2012.07.030 Peer Reviewed verified by ORBi |
 | Rizzoli, R., Cooper, C., Reginster, J.-Y., Abrahamsen, B., Adachi, J., Brandi, M., Bruyère, O., Compston, J., Ducy, P., Ferrari, S., Harvey, N., Kanis, J., Karsenty, G., Laslop, A., Rabenda, V., & Vestergaard, P. (2012). Antidepressant medications and osteoporosis. BONE, 51, 606-613. doi:10.1016/j.bone.2012.05.018 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Boonen, A., Rabenda, V., & REGINSTER, J.-Y. (2012). The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis. Expert Review of Pharmacoeconomics and Outcomes Research, 12 (2), 159-66. doi:10.1586/erp.12.8 Peer Reviewed verified by ORBi |
 | Bruyère, O., Rabenda, V., & Reginster, J.-Y. (2012). Utilisation d'une nouvelle définition de la progression radiologique pour prédire la future chirurgie du genou chez des patients arthrosiques. Revue du Rhumatisme, 79 (S1), 266. Peer Reviewed verified by ORBi |
 | Bruyère, O., Zegels, B., Leonori, L., Rabenda, V., Janssen, A., Bourges, C., & Reginster, J.-Y. (2012). Effect of collagen hydrolysate in articular pain: A 6-month randomized, double-blind, placebo controlled study. Complementary Therapies in Medicine, 20, 124-130. doi:10.1016/j.ctim.2011.12.007 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., & Rabenda, V. (24 March 2011). Basing adherence on empirical observations and how does partial adherence impact on anti-fracture efficacy [Paper presentation]. ECCEO-IOF 11 European Congress on Osteoporosis & Osteoarthritis, Valencia, Spain. |
 | Rabenda, V., Hiligsmann, M., & Reginster, J.-Y. (March 2011). Compliance to daily placebo treatment in a postmenopausal osteoporotic women population: characteristics and impact on mortality. Osteoporosis International, 22 (Suppl.1), 287-288. Peer Reviewed verified by ORBi |
 | Bruyère, O., Rabenda, V., & Reginster, J.-Y. (March 2011). A new definition of progressor in osteoarthritis clinical trial that takes into account intermediate visits: a proof of concept study. Osteoporosis International, 22 (Suppl.1), 367-368. Peer Reviewed verified by ORBi |
 | Rabenda, V., Bruyère, O., & Reginster, J.-Y. (2011). Relationship between bone mineral density changes and risk of fractures among patients receiving calcium with or without vitamin D supplementation: a meta-regression. Osteoporosis International, 22, 893-901. doi:10.1007/s00198-010-1469-x Peer Reviewed verified by ORBi |
 | Bruyère, O., Nicolet, D., Compère, S., Rabenda, V., Jeholet, P., Maassen, P., Pire, G., & Reginster, J.-Y. (2011). Perception, connaissance et utilisation de l'outil FRAX auprès des médecins généralistes de la Province de Liège (Belgique). Revue du Rhumatisme, 78 (S5), 142. Peer Reviewed verified by ORBi |
 | Kanis, J. A., Cooper, C., Hiligsmann, M., Rabenda, V., Reginster, J.-Y., & Rizzoli, R. (2011). Partial adherence: a new perspective on health economic assessment in osteoporosis. Osteoporosis International, 22 (10), 2565-73. doi:10.1007/s00198-011-1668-0 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Rabenda, V., Bruyère, O., & Reginster, J.-Y. (May 2010). The burden of non-adherence with oral bisphosphonates and the potential cost-effectiveness of adherence-enhancing interventions. Osteoporosis International, 21 (S1), 381. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Gathon, H.-J., Bruyère, O., Ethgen, O., Rabenda, V., & Reginster, J.-Y. (2010). Cost-Effectiveness of Osteoporosis Screening Followed by Treatment: The Impact of Medication Adherence. Value in Health, 13 (4), 394-401. doi:10.1111/j.1524-4733.2009.00687.x Peer Reviewed verified by ORBi |
 | Rabenda, V., Bruyère, O., & Reginster, J.-Y. (2010). Relationship between bone mineral density changes and risk of nonvertebral fractures among women receiving calcium with or without vitamin D supplementation: a meta-analysis. Osteoporosis International, 21 (Suppl.1), 268. Peer Reviewed verified by ORBi |
 | Rabenda, V., & Reginster, J.-Y. (2010). Prévention et traitement de l’ostéoporose: éviter l’inertie clinique et motiver l’adhésion au traitement. Revue Médicale de Liège, 65, 358-365. Peer reviewed |
 | Hiligsmann, M., Rabenda, V., Gathon, H.-J., Ethgen, O., & Reginster, J.-Y. (2010). Potential Clinical and Economic Impact of Nonadherence with Osteoporosis Medications. Calcified Tissue International, 86, 202-210. doi:10.1007/s00223-009-9329-4 Peer Reviewed verified by ORBi |
 | Rabenda, V., & Reginster, J.-Y. (2010). Positive impact of compliance to strontium ranelate on the risk of nonvertebral osteoporotic fractures. Osteoporosis International, 21 (12), 1993-2002. doi:10.1007/s00198-009-1155-z Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Rabenda, V., Bruyère, O., & Reginster, J.-Y. (2010). The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Health Policy, 96, 170-176. doi:10.1016/j.healthpol.2010.01.014 Peer reviewed |
 | Rabenda, V., & Reginster, J.-Y. (2010). Overcoming problems with adherence to osteoporosis medication. Expert Review of Pharmacoeconomics and Outcomes Research, 10 (6), 677-89. doi:10.1586/erp.10.76 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Rabenda, V., Bruyère, O., & Reginster, J.-Y. (October 2009). The clinical and economic burden of nonadherence with osteoporosis medications. Value in Health, 12 (7), 444. doi:10.1016/S1098-3015(10)75197-4 Peer Reviewed verified by ORBi |
 | Bruyère, O., COLLETTE, J., DEROISY, R., Rabenda, V., Neuprez, A., Hiligsmann, M., & Reginster, J.-Y. (October 2009). Biochemical markers of bone and cartilage remodelling: interest in the prediction of lumbar disc degeneration progression and effects of strontium ranelate over a 3-year period. Arthritis and Rheumatism, 60 (number 10 (suppl.)), 313. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Rabenda, V., Bruyère, O., & Reginster, J.-Y. (October 2009). The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Arthritis and Rheumatism, 60 (number 10 (suppl.)), 328. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Rabenda, V., & Reginster, J.-Y. (June 2009). The clinical and economic burden of nonadherence with oral bisphosphonates in osteoporotic patients. Annals of the Rheumatic Diseases, 68 (S3), 667. Peer Reviewed verified by ORBi |
 | Bruyère, O., Collette, J., Deroisy, R., Rabenda, V., Hiligsmann, M., & Reginster, J.-Y. (March 2009). Prediction of spinal osteoarthritis progression by assessment of biochemical markers of bone and cartilage remodelling: a 3-year study. Osteoporosis International, 20 (Suppl.1), 8. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Rabenda, V., Gathon, H.-J., Ethgen, O., & Reginster, J.-Y. (March 2009). Clinical en economic implications of non-adherence with osteoporosis medications. Osteoporosis International, 20 (S1), 16. Peer Reviewed verified by ORBi |
 | Rabenda, V., & Reginster, J.-Y. (March 2009). Positive impact of compliance to strontium ranelate on the risk of non-vertebral osteoporotic fractures. Osteoporosis International, 20 (Suppl.1), 89. Peer Reviewed verified by ORBi |
 | Rabenda, V., Bruyère, O., & Reginster, J.-Y. (March 2009). Relationship between changes in bone mineral density and compliance to strontium ranelate. Osteoporosis International, 20 (Suppl.1), 152-153. Peer Reviewed verified by ORBi |
 | Bruyère, O., Varela, A. R., Adami, S., Detilleux, J., Rabenda, V., Hiligsmann, M., & Reginster, J.-Y. (2009). Loss of hip bone mineral density over time is associated with spine and hip fracture incidence in osteoporotic postmenopausal women. European Journal of Epidemiology, 24, 707-712. doi:10.1007/s10654-009-9381-4 Peer Reviewed verified by ORBi |
 | Rabenda, V., Hiligsmann, M., & Reginster, J.-Y. (2009). Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence. Expert Opinion on Pharmacotherapy, 10 (14), 2303-15. doi:10.1517/14656560903140533 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Hiligsmann, M., Rabenda, V., Zegels, B., Neuprez, A., & Bruyère, O. (2009). Ibandronate in the management of postmenopausal osteoporosis. Clinical Medicine. Therapeutics, 1, 1409-1421. Peer reviewed |
 | Hiligsmann, M., Rabenda, V., Gathon, H.-J., Ethgen, O., Bruyère, O., & Reginster, J.-Y. (December 2008). Impact of medication non-compliance and non-persistence on pharmacoeconomic evaluations in osteoporosis. Osteoporosis International, 19 (S2), 282. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Rabenda, V., Gathon, H.-J., Ethgen, O., & Reginster, J.-Y. (November 2008). Impact of medication non-compliance and non-persistence on pharmacoeconomic evaluations in osteoporosis. Value in Health, 11 (6), 542. doi:10.1016/S1098-3015(10)66788-5 Peer Reviewed verified by ORBi |
 | Rabenda, V., & Reginster, J.-Y. (November 2008). Effet positif de l'observance au ranélate de strontium sur le risque de fractures ostéoporotiques non vertébrales. Revue du Rhumatisme, 75 (10-11), 1127. Peer Reviewed verified by ORBi |
 | Rabenda, V., & Reginster, J.-Y. (October 2008). Positive impact of compliance of strontium ranelate on the risk of nonvertebral osteoporotic fractures. Arthritis and Rheumatism, 58, 99. Peer Reviewed verified by ORBi |
 | Rabenda, V., & Reginster, J.-Y. (2008). Positive impact of compliance to strontium ranelate on the risk of nonvertebral osteoporotic fractures. Osteoporosis International, 19 (S2), 366-367. Peer Reviewed verified by ORBi |
 | Rabenda, V., Mertens, R., Fabri, V., Vanoverloop, J., Sumkay, F., Vannecke, C., Deswaef, A., Verpooten, G. A., & Reginster, J.-Y. (2008). Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporosis International, 19 (6), 811-8. doi:10.1007/s00198-007-0506-x Peer Reviewed verified by ORBi |
 | Rabenda, V., Vanoverloop, J., Fabri, V., Mertens, R., Sumkay, F., Vannecke, C., Deswaef, A., Verpooten, G. A., & Reginster, J.-Y. (2008). Low incidence of anti-osteoporosis treatment after hip fracture. Journal of Bone and Joint Surgery. American Volume, 90 (10), 2142-8. doi:10.2106/JBJS.G.00864 Peer Reviewed verified by ORBi |
 | Lekkerkerker, F., Kanis, J. A., Alsayed, N., Bouvenot, G., Burlet, N., Cahall, D., Chines, A., Delmas, P., Dreiser, R. L., Ethgen, D., Hughes, N., Kaufman, J. M., Korte, S., Kreutz, G., Laslop, A., Mitlak, B., Rabenda, V., Rizzoli, R., Santora, A., ... Reginster, J.-Y. (October 2007). Adherence to treatment of osteoporosis: a need for study. Osteoporosis International, 18 (10), 1311-1317. doi:10.1007/s00198-007-0410-4 Peer Reviewed verified by ORBi |
 | Rabenda, V., Fabri, V., Mertens, R., Vanoverloop, J., Deswaef, A., Verpooten, G., Vannecke, C., Thorre, K., & Reginster, J.-Y. (September 2007). Impact of poor adherence to bisphosphonates therapy on hip fracture risk in osteoporotic women. Arthritis and Rheumatism, 56 (number 9 (suppl.)), 271. Peer Reviewed verified by ORBi |
 | Rabenda, V., Fabri, V., Mertens, R., Vanoverloop, J., Deswaef, A., Verpooten, G., Vannecke, C., Thorre, K., & Reginster, J.-Y. (September 2007). Undertreatment with anti-osteoporotic drugs after hip fracture. Arthritis and Rheumatism, 56 (number 9 (suppl.)), 614. Peer Reviewed verified by ORBi |
 | Richy, F., Rabenda, V., Mawet, A., & Reginster, J.-Y. (August 2007). Flurbiprofen in the symptomatic management of rheumatoid arthritis: a valuable alternative. International Journal of Clinical Practice, 61 (8), 1396-1406. doi:10.1111/j.1742-1241.2007.01452.x Peer Reviewed verified by ORBi |
 | Rabenda, V., & Reginster, J.-Y. (March 2007). Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporosis International, 18 (Suppl.1), 19-20. Peer Reviewed verified by ORBi |
 | Rabenda, V., Mertens, R., Fabri, V., Vanoverloop, J., Sumkay, F., Thorre, K., Voisey, J., Vannecke, C., Deswaef, A., Verpooten, G., Devillers, J., & Reginster, J.-Y. (March 2007). Low incidence of osteoporosis treatment after hip fracture. Osteoporosis International, 18 (Suppl.1), 72-73. Peer Reviewed verified by ORBi |
 | Rabenda, V., Manette, C., Lemmens, R., Mariani, A. M., Struvay, N., & Reginster, J.-Y. (February 2007). Prevalence and impact of osteoarthritis and osteoporosis on health-related quality of life among active subjects. Aging Clinical and Experimental Research, 19 (1), 55-60. doi:10.1007/BF03325211 Peer Reviewed verified by ORBi |
 | Rabenda, V., Manette, C., Lemmens, R., Mariani, A. M., Struvay, N., & Reginster, J.-Y. (September 2006). The direct and indirect costs of the chronic management of osteoporosis: a prospective follow-up of 3440 active subjects. Osteoporosis International, 17 (9), 1346-1352. doi:10.1007/s00198-005-0066-x Peer Reviewed verified by ORBi |
 | Rabenda, V., Burlet, N., Belaiche, J., Raeman, F., Richy, F., & Reginster, J.-Y. (July 2006). Determinants of gastro-protective drugs co-prescription during treatment with nonselective NSAIDs: a prospective survey of 2197 patients recruited in primary care. Osteoarthritis and Cartilage, 14 (7), 625-630. doi:10.1016/j.joca.2006.01.002 Peer Reviewed verified by ORBi |
 | Rabenda, V., Manette, C., Lemmens, R., Mariani, A. M., Struvay, N., & Reginster, J.-Y. (June 2006). Direct and indirect costs attributable to osteoarthritis in active subjects. Journal of Rheumatology, 33 (6), 1152-1158. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Rabenda, V., & NEUPREZ, A. (April 2006). Adherence, patient preference and dosing frequency: Understanding the relationship. BONE, 38 (4 Suppl 1), 2-6. doi:10.1016/j.bone.2006.01.150 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., & Rabenda, V. (2006). Patient Preference in the Management of Postmenopausal Osteoporosis with Bisphosphonates. Clinical Interventions in Aging, 1 (4), 415-23. doi:10.2147/ciia.2006.1.4.415 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., & Rabenda, V. (2006). Adherence to anti-osteoporotic treatment: does it really matter? Future Rheumatology, 1, 37-40. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., & Rabenda, V. (05 October 2005). Observance et persistance: impact sur l'efficience des traitements de l'osteoporose. Revue Médicale Suisse, 1 (35), 2278-81. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Richy, F., Rabenda, V., & Tancredi, A. (June 2005). Global prevalence and skeletal implications of vitamin D inadequacy. Annals of the Rheumatic Diseases, 64 (Suppl.III), 362. Peer Reviewed verified by ORBi |
 | Rabenda, V., Burlet, N., Ethgen, O., Raeman, F., Belaiche, J., & Reginster, J.-Y. (May 2005). A naturalistic study of the determinants of health related quality of life improvement in osteoarthritic patients treated with non-specific non-steroidal antiinflammatory drugs. Annals of the Rheumatic Diseases, 64 (5), 688-693. doi:10.1136/ard.2004.026658 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Richy, F., Rabenda, V., & Tancredi, A. (March 2005). Vitamin D inadequacy: global prevalence and skeletal implications. Osteoporosis International, 16 (Suppl.3), 64. Peer Reviewed verified by ORBi |
 | Rabenda, V., Burlet, N., Ethgen, O., Raeman, F., BELAICHE, J., & Reginster, J.-Y. (March 2005). A naturalistic study of the determinants of healthrelated quality of life improvement in osteoarthritic patients treated with non-specific non-steroidal anti-inflammatory drugs. Osteoporosis International, 16 (Suppl.3), 100-101. Peer Reviewed verified by ORBi |
 | Rabenda, V., Manette, C., Lemmens, R., Mariani, A.-M., Struvay, N., & Reginster, J.-Y. (March 2005). Prevalence and impact of osteoarthritis and osteoporosis on health-related quality of life among active subjects. Osteoporosis International, 16 (Suppl.3), 110. Peer Reviewed verified by ORBi |
 | Rabenda, V., Manette, C., Lemmens, R., Mariani, A.-M., Struvay, N., & Reginster, J.-Y. (March 2005). Impact of health professionals utilization induced by musculoskeletal disorders among active subjects. Osteoporosis International, 16 (Suppl.3), 110. Peer Reviewed verified by ORBi |
 | Rabenda, V., MANETTE, C., Lemmens, R., Mariani, A. M., Struvay, N., & Reginster, J.-Y. (March 2005). Indirect costs induced by osteoarthritis and osteoporosis in the workplace. Osteoporosis International, 16 (Suppl.3), 13-14. Peer Reviewed verified by ORBi |
 | Rabenda, V., Burlet, N., BELAICHE, J., Raeman, F., Richy, F., & Reginster, J.-Y. (March 2005). Determinants of gastroprotective drugs co-prescription during treatment with non selective NSAIDS: A prospective survey of 2197 patients recruited in primary care. Osteoporosis International, 16 (Suppl.3), 101. Peer Reviewed verified by ORBi |
 | Rabenda, V., Hanssens, L., De Ceulaer, F., & Reginster, J.-Y. (2005). Is there any interest in combining treatments in osteoporosis? Current Rheumatology Reviews, 1, 49-55. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Richy, F., Rabenda, V., & tancredi, A. (2005). Vitamin D inadequacy : global prevalence and skeletal implications. BONE, 36 (S2), 462. Peer Reviewed verified by ORBi |
 | Richy, F., Bruyère, O., Ethgen, O., Rabenda, V., Bouvenot, G., Audran, M., Herrero-Beaumont, G., Moore, A., Eliakim, R., Haim, M., & Reginster, J.-Y. (July 2004). Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach [letter to the editor]. Annals of the Rheumatic Diseases, 63 (7), 759-766. doi:10.1136/ard.2003.015925 Peer Reviewed verified by ORBi |
 | Richy, F., Bruyère, O., Ethgen, O., Rabenda, V., Deceulaer, F., Bonvenot, G., Audran, M., Herrero-Beaumont Cuenca, G., Moore, A., Eliakim, R., Van De Putte, L., Haim, M., & Reginster, J.-Y. (November 2003). Time-dependent assessment of the gastrointestinal risk induced by low-dose aspirin intake: a meta-analysis. Osteoporosis International, 14 (Suppl. 7), 95. Peer Reviewed verified by ORBi |
 | Rabenda, V., Richy, F., Belaiche, J., Raeman, F., Haim, M., & Reginster, J.-Y. (November 2003). Incidence of gastrointestinal symptoms among patients taking conventional non-steroidal anti-inflammatory drugs: a pragmatic study in 1946 Belgian outpatients. Osteoporosis International, 14 (Suppl. 7), 90. Peer Reviewed verified by ORBi |
 | Rabenda, V., Belaiche, J., Raeman, F., Haim, M., & Reginster, J.-Y. (November 2003). Use of healthcare resources related to gastrointestinal toxicity of NSAIDS. Osteoporosis International, 14 (Suppl. 7), 14. Peer Reviewed verified by ORBi |
 | Rabenda, V., Ethgen, O., Belaiche, J., Raeman, F., Haim, M., & Reginster, J.-Y. (November 2003). Impact of osteoarthritis and chronic back pain on health-related quality of life among patients on NSAIDS. Osteoporosis International, 14 (Suppl. 7), 89-90. Peer Reviewed verified by ORBi |
 | Ethgen, O., Rabenda, V., Bruyère, O., & Reginster, J.-Y. (November 2003). Projecting the prevalence of osteoarthritis and osteoporosis over the five forthcoming decades: their increasing impact on public health. Osteoporosis International, 14 (Suppl. 7), 65-66. Peer Reviewed verified by ORBi |
 | Richy, F., Bruyère, O., Ethgen, O., Rabenda, V., Bouvenot, G., Audran, M., Herrero Beaumont Cuenca, G., Moore, A., Eliakim, R., Van De Putte, L., Haim, M., & Reginster, J.-Y. (November 2003). Time-dependent risk of gastrointestinal complications induced by NSAIDS use: a consensus statement using meta-analytic approach. Osteoporosis International, 14 (Suppl. 7), 9. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Tancredi, A., & Rabenda, V. (2003). Glucosamine Sulphate in Osteoarthritis. Business Briefing : Long Term Healthcare Strategies, 57-60. |
 | Rabenda, V., Boniver, J., & Reginster, J.-Y. (2003). Numerus clausus en fin de troisieme candidature en medecine: mort annoncee d'une heresie? Revue Médicale de Liège, 58 (7-8, Jul-Aug), 508-14. Peer reviewed |